"For children and families living with Lennox-Gastaut syndrome, every day can be challenging, facing unpredictable and life-limiting seizures, and this new treatment option on the NHS will now offer new hope, giving many the chance for greater stability and a better quality of life.
"In recommending fenfluramine, the independent committee took into account the rarity and severity of Lennox Gastaut syndrome, the significant impact it has on the quality of life of people with the condition and their families and carers, and the high need for effective treatments, particularly for people who aren't able to take cannabidiol with clobazam.
"It's fantastic news for hundreds of families that there's a proven, evidence-based new medicine that can be taken at home to help control and reduce their child's seizures and, for example, lower the risk of them experiencing injuries and needing to go to hospital," he said.
Hundreds of children with a rare and severe form of epilepsy are hoping a new drug being rolled out on the NHS may provide a better quality of life.
Clinical trials suggest fenfluramine can cut the frequency of seizures that cause patients to lose consciousness and muscle control, known as drop seizures, by 26.5% on average.
